Assessment of cardio-ankle vascular index in patients with abdominal aortic aneurysm: An observational study. (April 2021)

• Record Type: Journal Article
• Authors: Aykan, Ahmet Çağrı; Çetin, Mustafa; Kalaycıoğlu, Ezgi; Menteşe, Ümit
• Is Part Of: Vascular. Volume 29:Number 2(2021)
• Page Start: 190
• Page End: 195
• Publication Date: 2021-04
• Subjects: CAVI -- arterial stiffness -- abdominal aortic aneurysm; 616.13
• DOI: 10.1177/1708538120946549
• Languages: English
• ISSNs: 1708-5381

Abstract

Objectives: Arterial stiffness is associated with major adverse cardiovascular events. The aim of this study is to investigate arterial stiffness by cardio-ankle vascular index (CAVI) in patients with abdominal aortic aneurysm (AAA). Methods: This observational and cross-sectional study involved 59 subjects with AAA and 32 healthy subjects. All subjects underwent ultrasonography examination. CAVI was measured by VaSera-1000 CAVI instrument. Results: Mean abdominal aortic diameter of AAA patients and controls were 43.88 ± 9.28 mm and 20.43 ± 3.14 mm, consecutively. Baseline clinical characteristics of the patients and controls were similar for age, presence of hypertension, diabetes, dyslipidemia, coronary artery disease and smoking. Left ventricle ejection fraction and Left ventricle mass index (LVMI) were similar between groups. CAVI was significantly higher in patients with AAA than controls (9.74 ± 1.50 vs. 7.60 ± 1.07, p < 0.001). CAVI was positively correlated with AAA diameter ( r = 0.461, p < 0.001) and negatively correlated with left ventricle ejection fraction ( r = –0.254, p = 0.015). CAVI >8.3 had a sensitivity 89.8% and a specificity of 78.1% for predicting the presence of AAA in ROC analysis (area under curve = 0.897, 95%CI = 0.816–0.951, p < 0.001). Conclusion: CAVI is increased in patients with AAA. Increased arterial stiffness may be a mechanical link between AAA, coronary artery disease and peripheral artery disease or a common mechanism effects the arterial stiffness, coronary artery disease, peripheral artery disease and AAA. Therefore, CAVI may be used as a valuable marker for risk stratification for the development of AAA in susceptible patients.